Prospective evaluation of minimal residual disease in the phase II FORTE trial: a head-to-head comparison between multiparameter flow cytometry and next-generation sequencing
Key Points
Key points are not available for this paper at this time.
Abstract
Amgen, Celgene/Bristol Myers Squibb, Multiple Myeloma Research Foundation.
اسأل الذكاء الاصطناعي
Like
Bookmark
Share
View Full Paper
اسأل الذكاء الاصطناعي
Like
Bookmark
Share
View Full Paper
Prospective evaluation of minimal residual disease in the phase II FORTE trial: a head-to-head comparison between multiparameter flow cytometry and next-generation sequencing | Synapse